COMP <GO>
GRMN vs TMO // ENTERPRISE SCALE & MARKET CAP
Garmin Ltd. Common Stock (Switzerland) (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: GRMN 11
— TMO 3
▲ ENTERPRISE SCALE & MARKET CAP LEADER: TMO
LAST: $272.67 (-2.60%) • MKT CAP: $53.94B
market-cap
$53.94B
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
market-cap
$262.22B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GRMN VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GRMN | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 58.70% | 41.00% | +17.70 | GRMN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.60% | 9.30% | +7.30 | GRMN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 25.6x | 30.4x | -4.80 | GRMN | /valuation <GO> |
| Free Cash Flow Yield | 2.53% | 2.40% | +0.13 | GRMN | /fcf-yield <GO> |
| Operating Margin | 25.90% | 17.40% | +8.50 | GRMN | /operating-margins <GO> |
| Net Profit Margin | 23.00% | 15.10% | +7.90 | GRMN | /net-margins <GO> |
| Revenue Growth (YoY) | 15.10% | 3.90% | +11.20 | GRMN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.23% | 0.24% | +0.99 | GRMN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.74 | 4.50 | +4.24 | GRMN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 6.70% | -0.10 | GRMN | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.2 | 59.1 | -17.91 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.92 | 0.94 | -0.02 | TMO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.2x | 36.3x | -9.10 | GRMN | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $53.94B | $262.22B | -$208.27B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GRMN REV | TMO REV | GRMN GROSS % | TMO GROSS % | GRMN FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $7.25B | $44.56B | 58.7% | 44.0% | $1.36B | $6.29B |
| FY 2024 | $6.30B | $42.88B | 58.7% | 44.0% | $1.24B | $7.27B |
| FY 2023 | $5.23B | $42.86B | 44.0% | 44.0% | $1.14B | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GRMN // BETA 0.92
TMO // BETA 0.94